Back to search
FDAFDA · Food and drugs·Recall number D-0921-2017

Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.

Published June 28, 2017 · Recall initiated: June 1, 2017

Summary

FDA records drug Class II recall D-0921-2017, published June 28, 2017 and initiated June 1, 2017. Recalling firm: Lucid Pharma LLC; Status: Terminated; Reported quantity: a) 44168 bottles; b) 24960 bottles; Lot: Lot #: a) V17516045-A, Exp 08/18; b) V17516047-A 09/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lucid Pharma LLC
Distributor
Nationwide in the USA
Lot
Lot #: a) V17516045-A, Exp 08/18; b) V17516047-A 09/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA. recalled?

Yes. FDA published recall D-0921-2017 on June 28, 2017. Reported hazard: Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.

What should I do if I have this product?

Voluntary: Firm initiated · Letter